Supplementary Table S1. Number of participants with values below limit of detection (LOD) and corresponding percentage out of the total number of participants included in the analyses for each of the ratios.

Ratio	Sample N <lod< th=""><th>Sample N<lod< th=""><th>Sample N<lod< th=""><th>Sample N<lod< th=""></lod<></th></lod<></th></lod<></th></lod<>	Sample N <lod< th=""><th>Sample N<lod< th=""><th>Sample N<lod< th=""></lod<></th></lod<></th></lod<>	Sample N <lod< th=""><th>Sample N<lod< th=""></lod<></th></lod<>	Sample N <lod< th=""></lod<>
	MEHP	MEHHP	MECPP	MEOHP
logpercentMEHP	1,612 (30.6%)	28 (0.5%)	3 (0.1%)	69 (1.3%)
MEHHP:MECPP		29 (0.6%)	4 (0.1%)	
МЕНР:МЕННР	1,801 (28.2%)	46 (0.7%)		
MEHHP:MEOHP		56 (0.9%)		116 (1.8%)
MEOHP:MECPP			3 (0.1%)	69 (1.3%)

Note: The values <LOD are substituted with LOD divided by square root of 2 in the analysis.

Supplementary Table S2. Associations of Individual Characteristics and Lifestyle Factors With MEHHP:MECPP (Regression Estimates and 95% Confidence Intervals) NHANES 2001-2012.

	All parti	icipants		Participants with no prescription medication use in				
Model 1 ^a		Model 2 ^b		Model 1 ^a		Model 2 ^b		
β	95% CI	β	95% CI	β	95% CI	β	95% CI	
-0.001	-0.001, -0.001	-0.001	-0.002, -0.001	0.001	-0.001, 0.001	-0.001	-0.001, 0.001	
0.000	Reference	0.000	Reference	0.000	Reference	0.000	Reference	
-0.062	-0.099, -0.025	-0.048	-0.087, -0.009	-0.024	-0.070, 0.021	-0.010	-0.056, 0.037	
-0.042	-0.061, -0.025	-0.027	-0.047, -0.007	-0.023	-0.047, 0.001	-0.010	-0.035, 0.015	
0.103	0.068, 0.139	0.121	0.087, 0.155	0.115	0.068, 0.163	0.132	0.086, 0.179	
0.000	Reference	0.000	Reference	0.000	Reference	0.000	Reference	
-0.033	-0.053, -0.013	-0.033	-0.053, -0.012	-0.057	-0.085, -0.029	-0.051	-0.079, -0.022	
0.000	Reference	0.000	Reference	0.000	Reference	0.000	Reference	
0.047	-0.025, 0.120	0.044	-0.028, 0.116	-0.011	-0.097, 0.076	-0.012	-0.101, 0.076	
0.002	-0.021, 0.026	0.003	-0.020, 0.026	0.003	-0.026, 0.032	0.005	-0.024, 0.034	
0.000	Reference	0.000	Reference	0.000	Reference	0.000	Reference	
0.009	-0.019, 0.037	0.002	-0.026, 0.031	0.023	-0.013, 0.060	0.016	-0.020, 0.051	
0.040	0.012, 0.068	0.028	0.001, 0.055	0.031	0.005, 0.058	0.021	-0.006, 0.049	
0.000	Reference	0.000	Reference	0.000	Reference	0.000	Reference	
0.017	-0.012, 0.046	0.016	-0.012, 0.044	0.012	-0.035, 0.059	0.010	-0.038, 0.058	
0.073	0.030, 0.117	0.066	0.023, 0.110	0.074	-0.001, 0.148	0.067	-0.007, 0.142	
0.000	Reference	0.000	Reference	0.000	Reference	0.000	Reference	
-0.022	-0.065, 0.021	-0.025	-0.068, 0.019	0.031	-0.047, 0.109	0.029	-0.048, 0.106	
	β -0.001 0.000 -0.062 -0.042 0.103 0.000 -0.033 0.000 0.047 0.002 0.000 0.009 0.040 0.007 0.073 0.000	Model 1 a β 95% CI -0.001 -0.001, -0.001 0.000 Reference -0.062 -0.099, -0.025 -0.042 -0.061, -0.025 0.103 0.068, 0.139 0.000 Reference -0.033 -0.053, -0.013 0.000 Reference 0.047 -0.025, 0.120 0.002 -0.021, 0.026 0.009 -0.019, 0.037 0.040 0.012, 0.068 0.000 Reference 0.012, 0.046 0.073 0.030, 0.117 0.000 Reference	β 95% CI β -0.001 -0.001, -0.001 -0.001 0.000 Reference 0.000 -0.062 -0.099, -0.025 -0.048 -0.042 -0.061, -0.025 -0.027 0.103 0.068, 0.139 0.121 0.000 Reference 0.000 -0.033 -0.053, -0.013 -0.033 0.000 Reference 0.000 0.047 -0.025, 0.120 0.044 0.002 -0.021, 0.026 0.003 0.000 Reference 0.000 0.040 0.012, 0.048 0.028 0.000 Reference 0.000 0.017 -0.012, 0.046 0.016 0.073 0.030, 0.117 0.066 0.000 Reference 0.000	Model 1 a Model 2 b β 95% CI β 95% CI -0.001 -0.001, -0.001 -0.002, -0.001 0.000 Reference 0.000 Reference -0.062 -0.099, -0.025 -0.048 -0.087, -0.009 -0.042 -0.061, -0.025 -0.027 -0.047, -0.007 0.103 0.068, 0.139 0.121 0.087, 0.155 0.000 Reference 0.000 Reference -0.033 -0.053, -0.013 -0.033 -0.053, -0.012 0.000 Reference 0.000 Reference 0.047 -0.025, 0.120 0.044 -0.028, 0.116 0.002 -0.021, 0.026 0.003 -0.020, 0.026 0.000 Reference 0.000 Reference 0.009 -0.019, 0.037 0.002 -0.026, 0.031 0.040 0.012, 0.068 0.028 0.001, 0.055 0.000 Reference 0.000 Reference 0.017 -0.012, 0.046 0.016 -0.012, 0.044	Model 1a Model 2b M β 95% CI β 95% CI β -0.001 -0.001, -0.001 -0.002, -0.001 0.001 0.000 Reference 0.000 Reference 0.000 -0.062 -0.099, -0.025 -0.048 -0.087, -0.009 -0.024 -0.042 -0.061, -0.025 -0.027 -0.047, -0.007 -0.023 0.103 0.068, 0.139 0.121 0.087, 0.155 0.115 0.000 Reference 0.000 Reference 0.000 -0.033 -0.053, -0.013 -0.053, -0.012 -0.057 0.000 Reference 0.000 Reference 0.000 0.047 -0.025, 0.120 0.044 -0.028, 0.116 -0.011 0.002 -0.021, 0.026 0.003 -0.020, 0.026 0.003 0.009 -0.019, 0.037 0.002 -0.026, 0.031 0.023 0.040 0.012, 0.068 0.028 0.001, 0.055 0.031 0.000 Reference 0.000	Model 1 aModel 2 bModel 1 aβ95% CIβ95% CIβ95% CI-0.001-0.001, -0.001-0.002, -0.0010.001-0.001, 0.0010.000Reference0.000Reference0.000Reference-0.062-0.099, -0.025-0.048-0.087, -0.009-0.024-0.070, 0.021-0.042-0.061, -0.025-0.027-0.047, -0.007-0.023-0.047, 0.0010.1030.068, 0.1390.1210.087, 0.1550.1150.068, 0.1630.000Reference0.000Reference0.000Reference-0.033-0.053, -0.013-0.033-0.053, -0.012-0.057-0.085, -0.0290.000Reference0.000Reference0.000Reference0.047-0.025, 0.1200.044-0.028, 0.116-0.011-0.097, 0.0760.002-0.021, 0.0260.003-0.020, 0.0260.003-0.026, 0.0320.000Reference0.000Reference0.000Reference0.009-0.019, 0.0370.002-0.026, 0.0310.023-0.013, 0.0600.0400.012, 0.0480.0280.001, 0.0550.0310.005, 0.0580.000Reference0.000Reference0.000Reference0.017-0.012, 0.0460.016-0.012, 0.0440.012-0.035, 0.0590.0730.030, 0.1170.0660.023, 0.1100.074-0.001, 0.148	Model 1a Model 2b Model 1a M β 95% CI β 95% CI β 95% CI β -0.001 -0.001, -0.001 -0.001 -0.002, -0.001 0.001 -0.001, 0.001 -0.001 0.000 Reference 0.000 Reference 0.000 0.001 -0.001, 0.001 -0.001 -0.062 -0.099, -0.025 -0.048 -0.087, -0.009 -0.024 -0.070, 0.021 -0.010 -0.042 -0.061, -0.025 -0.027 -0.047, -0.007 -0.023 -0.047, 0.001 -0.010 0.103 0.068, 0.139 0.121 0.087, 0.155 0.115 0.068, 0.163 0.132 0.000 Reference 0.000 Reference 0.000 Reference 0.000 -0.033 -0.53, -0.013 -0.033 -0.057 -0.085, -0.029 -0.051 0.000 Reference 0.000 Reference 0.000 Reference 0.000 0.047 -0.025, 0.120 0.044 -0.028, 0.116 -0.011	

Characteristic		All participants				Participants with no prescription medication use in the past month				
	Model 1 ^a		Model 2 ^b		Model 1 a		Model 2 ^b			
	β	95% CI	β	95% CI	β	95% CI	β	95% CI		
Caffeine, mg ^c			-		-					
1 st quartile	0.000	Reference	0.000	Reference	0.000	Reference	0.000	Reference		
2 nd quartile	0.037	0.004, 0.071	0.036	0.004, 0.069	0.027	-0.018, 0.071	0.027	-0.017, 0.072		
3 rd quartile	0.042	0.014, 0.069	0.038	0.010, 0.065	0.027	-0.010, 0.064	0.027	-0.011, 0.065		
4 th quartile	0.050	0.019, 0.080	0.042	0.012, 0.072	0.049	0.013, 0.084	0.046	0.009, 0.083		
Prescription medication in the past		,		,		,		,		
month										
None	0.000	Reference	0.000	Reference	NA	NA	NA	NA		
Any	0.029	0.008, 0.050	0.031	0.009, 0.053	NA	NA	NA	NA		
Menopausal status/hormone use		,		,						
(women only)										
Premenopausal	0.000	Reference	0.000	Reference	0.000	Reference	0.000	Reference		
Postmenopausal/Never used	-0.068	-0.134, -0.002	-0.073	-0.140, -0.006	-0.057	-0.113, -0.002	-0.066	-0.124, -0.008		
Postmenopausal/Past, not current	-0.023	-0.098, 0.053	-0.030	-0.106, 0.045	0.030	-0.098, 0.159	0.021	-0.111, 0.153		
Postmenopausal/Past, unknown current	-0.055	-0.156, 0.045	-0.068	-0.168, 0.033	-0.221	-0.453, 0.011	-0.197	-0.419, 0.024		
Postmenopausal/Current	0.078	-0.012, 0.167	0.059	-0.035, 0.153	NA	NA	NA	NA		

Abbreviations: CI, Confidence Interval; NA, Not Applicable

^a Adjusted for age, BMI, and race

^b Adjusted for age, BMI, race, and all other factors in the analyses

^c 1st quartile <10; 2nd quartile 10-<91; 3rd quartile 91-<208; and 4th quartile ≥208 mg

Supplementary Table S3. Associations of Individual Characteristics and Lifestyle Factors With MEOHP:MECPP (Regression Estimates and 95% Confidence Intervals), NHANES 2001-2012.

		All parti	icipants		Participants with no prescription medication use in				
Characteristic						the past			
	Model 1 a		Model 2 ^b		Model 1 ^a		Model 2 ^b		
	β	95% CI	β	95% CI	β	95% CI	β	95% CI	
Age (continuous)									
Estimates	-0.001	-0.001, -0.001	-0.001	-0.001, -0.001	-0.001	-0.001, 0.001	-0.001	-0.001, 0.001	
Race									
Caucasian	0.000	Reference	0.000	Reference	0.000	Reference	0.000	Reference	
Other Race	-0.032	-0.055, -0.009	-0.025	-0.050, -0.001	-0.008	-0.033, 0.018	-0.004	-0.030, 0.022	
Mexican-American or other Hispanic	-0.031	-0.042, -0.020	-0.024	-0.035, -0.012	-0.022	-0.035, -0.009	-0.019	-0.033, -0.004	
Non-Hispanic Black	0.050	0.031, 0.069	0.058	0.039, 0.077	0.057	0.030, 0.083	0.062	0.035, 0.089	
Gender									
Male	0.000	Reference	0.000	Reference	0.000	Reference	0.000	Reference	
Female	0.009	-0.001, 0.020	0.010	-0.002, 0.021	-0.001	-0.015, 0.015	0.001	-0.015, 0.017	
Body Mass Index									
Normal	0.000	Reference	0.000	Reference	0.000	Reference	0.000	Reference	
Underweight	0.033	-0.013, 0.080	0.031	-0.015, 0.077	-0.002	-0.060, 0.056	-0.005	-0.063, 0.053	
Overweight	0.003	-0.011, 0.017	0.004	-0.010, 0.018	-0.001	-0.015, 0.015	0.001	-0.014, 0.016	
Smoking									
Never smoker	0.000	Reference	0.000	Reference	0.000	Reference	0.000	Reference	
Past smoker	0.008	-0.009, 0.024	0.005	-0.012, 0.022	0.006	-0.013, 0.025	0.004	-0.015, 0.024	
Current smoker	0.019	0.007, 0.031	0.017	0.005, 0.029	0.011	-0.004, 0.025	0.010	-0.006, 0.026	
Alcohol use									
None	0.000	Reference	0.000	Reference	0.000	Reference	0.000	Reference	
Below limit	0.011	-0.006, 0.027	0.010	-0.006, 0.026	-0.016	-0.044, 0.012	-0.017	-0.045, 0.011	
Above limit	0.011	-0.009, 0.032	0.008	-0.012, 0.028	-0.017	-0.054, 0.019	-0.021	-0.057, 0.016	
Cancer history									
No	0.000	Reference	0.000	Reference	0.000	Reference	0.000	Reference	
Yes	-0.003	-0.027, 0.021	-0.004	-0.028, 0.020	0.015	-0.033, 0.064	0.017	-0.031, 0.066	

Characteristic		All parti	icipants		Participants with no prescription medication use in the past month				
	Model 1 a		N	Model 2 ^b		Model 1 a		lodel 2 ^b	
	β	95% CI	β	95% CI	β	95% CI	β	95% CI	
Caffeine, mg ^c					-				
1 st quartile	0.000	Reference	0.000	Reference	0.000	Reference	0.000	Reference	
2 nd quartile	0.019	0.005, 0.034	0.019	0.004, 0.033	0.018	-0.005, 0.040	0.018	-0.005, 0.041	
3 rd quartile	0.019	0.004, 0.034	0.017	0.003, 0.032	0.007	-0.016, 0.030	0.007	-0.017, 0.031	
4 th quartile	0.023	0.007, 0.039	0.019	0.003, 0.035	0.023	0.002, 0.044	0.023	0.001, 0.044	
Prescription medication in past month									
None	0.000	Reference	0.000	Reference	NA	NA	NA	NA	
Any	0.014	0.002, 0.027	0.014	0.002, 0.027	NA	NA	NA	NA	
Menopausal status/hormone use									
(women only)									
Premenopausal	0.000	Reference	0.000	Reference	0.000	Reference	0.000	Reference	
Postmenopausal/Never used	-0.039	-0.074, -0.003	-0.043	-0.080, -0.007	-0.020	-0.053, 0.014	-0.027	-0.062, 0.008	
Postmenopausal/Past, not current	-0.030	-0.070, 0.010	-0.037	-0.077, 0.003	0.003	-0.075, 0.081	-0.003	-0.083, 0.076	
Postmenopausal/Past, unknown current	-0.016	-0.071, 0.038	-0.024	-0.079, 0.031	-0.101	-0.246, 0.043	-0.105	-0.256, 0.045	
Postmenopausal/Current	0.047	-0.004, 0.098	0.035	-0.018, 0.088	NA	NA	NA	NA	

Abbreviations: CI, Confidence Interval; NA, Not Applicable

^a Adjusted for age, BMI, and race

^b Adjusted for age, BMI, race, and all other factors in the analyses

^c 1st quartile <10; 2nd quartile 10-<91; 3rd quartile 91-<208; and 4th quartile ≥208 mg

Supplementary Table S4. Associations of Individual Characteristics and Lifestyle Factors With MEHHP:MEOHP (Regression Estimates and 95% Confidence Intervals) NHANES 2001-2012.

	All parti	icipants		Participants with no prescription medication use in the past month				
Model 1 a		Model 2 b		Model 1 a		Model 2 ^b		
β	95% CI	β	95% CI	β	95% CI	β	95% CI	
0.001	-0.001, 0.001	-0.001	-0.001, 0.001	0.001	-0.001, 0.002	0.001	-0.001, 0.002	
	Reference						Reference	
-0.003	-0.063, 0.058	0.012	-0.048, 0.072	-0.006	-0.071, 0.060	0.021	-0.044, 0.086	
-0.003	-0.039, 0.032	0.010	-0.026, 0.046	0.013	-0.032, 0.058	0.030	-0.014, 0.075	
0.040	-0.007, 0.087	0.052	0.003, 0.102	0.046	-0.006, 0.098	0.064	0.010, 0.117	
0.000	Reference	0.000	Reference	0.000	Reference	0.000	Reference	
-0.112	-0.142, -0.082	-0.108	-0.138, -0.077	-0.133	-0.173, -0.092	-0.119	-0.159, -0.079	
0.000	Reference	0.000	Reference	0.000	Reference	0.000	Reference	
-0.004	-0.083, 0.076	-0.005	-0.085, 0.075	-0.032	-0.134, 0.070	-0.031	-0.135, 0.074	
-0.013	-0.045, 0.019	-0.015	-0.046, 0.016	0.005	-0.043, 0.052	0.004	-0.042, 0.051	
0.000	Reference	0.000	Reference	0.000	Reference	0.000	Reference	
0.009	-0.022, 0.039	-0.005	-0.037, 0.028	0.030	-0.021, 0.081	0.015	-0.032, 0.062	
0.059	0.018, 0.101	0.033	-0.006, 0.073	0.051	0.001, 0.101	0.023	-0.020, 0.067	
0.000	Reference	0.000	Reference	0.000	Reference	0.000	Reference	
-0.044	-0.093, 0.005	-0.042	-0.089, 0.006	0.042	-0.018, 0.102	0.042	-0.018, 0.101	
0.110	0.032, 0.188	0.102	0.026, 0.178	0.230	0.113, 0.347	0.222	0.109, 0.334	
0.000	Reference	0.000	Reference	0.000	Reference	0.000	Reference	
-0.040	-0.095, 0.014	-0.042	-0.095, 0.011	-0.002	-0.121, 0.116	-0.009	-0.124, 0.105	
	β 0.001 0.000 -0.003 -0.003 0.040 0.000 -0.112 0.000 -0.013 0.000 0.009 0.059 0.000 -0.044 0.110 0.000	Model 1 a β 95% CI 0.001 -0.001, 0.001 0.000 Reference -0.003 -0.063, 0.058 -0.003 -0.039, 0.032 0.040 -0.007, 0.087 0.000 Reference -0.112 -0.142, -0.082 0.000 Reference -0.044 -0.083, 0.076 -0.013 -0.045, 0.019 0.009 -0.022, 0.039 0.059 0.018, 0.101 0.000 Reference -0.044 -0.093, 0.005 0.110 0.032, 0.188 0.000 Reference	β 95% CI β 0.001 -0.001, 0.001 -0.001 0.000 Reference 0.000 -0.003 -0.063, 0.058 0.012 -0.003 -0.039, 0.032 0.010 0.040 -0.007, 0.087 0.052 0.000 Reference 0.000 -0.112 -0.142, -0.082 -0.108 0.000 Reference 0.005 -0.013 -0.045, 0.019 -0.015 0.000 Reference 0.000 0.009 -0.022, 0.039 -0.005 0.059 0.018, 0.101 0.033 0.000 Reference 0.000 -0.044 -0.093, 0.005 -0.042 0.110 0.032, 0.188 0.102 0.000 Reference 0.000	Model 1 a Model 2 b β 95% CI β 95% CI 0.001 -0.001, 0.001 -0.001, 0.001 -0.001, 0.001 0.000 Reference 0.000 Reference -0.003 -0.063, 0.058 0.012 -0.048, 0.072 -0.003 -0.039, 0.032 0.010 -0.026, 0.046 0.040 -0.007, 0.087 0.052 0.003, 0.102 0.000 Reference 0.000 Reference -0.112 -0.142, -0.082 -0.108 -0.138, -0.077 0.000 Reference 0.000 Reference -0.004 -0.083, 0.076 -0.005 -0.085, 0.075 -0.013 -0.045, 0.019 -0.015 -0.046, 0.016 0.000 Reference 0.000 Reference 0.009 -0.022, 0.039 -0.005 -0.037, 0.028 0.059 0.018, 0.101 0.033 -0.006, 0.073 0.000 Reference 0.000 Reference -0.044 -0.093, 0.005 -0.042 -0.089, 0.	Model 1 a Model 2 b M β 95% CI β 95% CI β 0.001 -0.001, 0.001 -0.001, 0.001 0.001 0.000 Reference 0.000 Reference 0.000 -0.003 -0.063, 0.058 0.012 -0.048, 0.072 -0.006 -0.003 -0.039, 0.032 0.010 -0.026, 0.046 0.013 0.040 -0.007, 0.087 0.052 0.003, 0.102 0.046 0.000 Reference 0.000 Reference 0.000 -0.112 -0.142, -0.082 -0.108 -0.138, -0.077 -0.133 0.000 Reference 0.000 Reference 0.000 -0.004 -0.083, 0.076 -0.005 -0.085, 0.075 -0.032 -0.013 -0.045, 0.019 -0.015 -0.046, 0.016 0.005 0.000 Reference 0.000 Reference 0.000 0.009 -0.022, 0.039 -0.005 -0.037, 0.028 0.030 0.059 0.018, 0.101	Model 1 a Model 2 b Model 1 a β 95% CI β 95% CI β 95% CI 0.001 -0.001, 0.001 -0.001, 0.001 0.001 -0.001, 0.002 0.000 Reference 0.000 Reference -0.003 -0.063, 0.058 0.012 -0.048, 0.072 -0.006 -0.071, 0.060 -0.003 -0.039, 0.032 0.010 -0.026, 0.046 0.013 -0.032, 0.058 0.040 -0.007, 0.087 0.052 0.003, 0.102 0.046 -0.032, 0.058 0.000 Reference 0.000 Reference 0.006, 0.098 0.000 Reference 0.000 Reference 0.006, 0.098 0.000 Reference 0.000 Reference 0.000 Reference -0.012 -0.142, -0.082 -0.108 -0.138, -0.077 -0.133 -0.173, -0.092 0.000 Reference 0.000 Reference 0.000 Reference -0.044 -0.083, 0.076 -0.005 -0.085, 0.075 -0.032	Model 1aModel 2bModel 1aModel 1aMβ95% CIβ95% CIβ95% CIβ0.001-0.001, 0.001-0.001, 0.0010.001-0.001, 0.0020.0010.000Reference0.000Reference0.000Reference0.000-0.003-0.063, 0.0580.012-0.048, 0.072-0.006-0.071, 0.0600.021-0.003-0.039, 0.0320.010-0.026, 0.0460.013-0.032, 0.0580.0300.040-0.007, 0.0870.0520.003, 0.1020.046-0.006, 0.0980.0640.000Reference0.000Reference0.000Reference0.000Reference0.000-0.112-0.142, -0.082-0.108-0.138, -0.077-0.133-0.173, -0.092-0.1190.000Reference0.000Reference0.000Reference0.000-0.013-0.045, 0.019-0.015-0.085, 0.075-0.032-0.134, 0.070-0.031-0.013-0.045, 0.019-0.015-0.046, 0.0160.005-0.043, 0.0520.0040.000Reference0.000Reference0.000Reference0.0000.009-0.022, 0.039-0.005-0.037, 0.0280.030-0.021, 0.0810.0150.0590.018, 0.1010.033-0.006, 0.0730.0510.001, 0.1010.0230.000Reference0.000Reference0.000Reference0.0000.044-0.093, 0.005-0.04	

Characteristic		All participants				Participants with no prescription medication use in the past month				
-	Model 1 ^a		Model 2 ^b		Model 1 a		Model 2 ^b			
-	β	95% CI	β	95% CI	β	95% CI	β	95% CI		
Caffeine, mg ^c			-		-		-			
1 st quartile	0.000	Reference	0.000	Reference	0.000	Reference	0.000	Reference		
2 nd quartile	-0.009	-0.057, 0.039	-0.009	-0.056, 0.039	-0.032	-0.086, 0.023	-0.029	-0.082, 0.023		
3 rd quartile	0.030	-0.021, 0.081	0.021	-0.031, 0.073	0.029	-0.030, 0.088	0.029	-0.029, 0.087		
4 th quartile	0.040	-0.006, 0.087	0.026	-0.022, 0.074	0.030	-0.041, 0.101	0.021	-0.049, 0.092		
Prescription medication in past month										
None	0.000	Reference	0.000	Reference	NA	NA	NA	NA		
Any	0.022	-0.011, 0.056	0.024	-0.009, 0.056	NA	NA	NA	NA		
Menopausal status/hormone use										
(women only)										
Premenopausal	0.000	Reference	0.000	Reference	0.000	Reference	0.000	Reference		
Postmenopausal/Never used	-0.033	-0.116, 0.050	-0.032	-0.115, 0.051	-0.090	-0.201, 0.022	-0.081	-0.190, 0.027		
Postmenopausal/Past, not current	0.086	-0.014, 0.186	0.091	-0.010, 0.191	0.083	-0.095, 0.262	0.093	-0.082, 0.269		
Postmenopausal/Past, unknown current	-0.099	-0.213, 0.015	-0.106	-0.221, 0.010	-0.003	-0.347, 0.341	0.084	-0.239, 0.406		
Postmenopausal/Current	-0.052	-0.158, 0.055	-0.064	-0.174, 0.046	NA	NA	NA	NA		

Abbreviations: CI, Confidence Interval; NA, Not Applicable

^a Adjusted for age, BMI, and race

^b Adjusted for age, BMI, race, and all other factors in the analyses

^c 1st quartile <10; 2nd quartile 10-<91; 3rd quartile 91-<208; and 4th quartile ≥208 mg